Drug intelligence / Profile preview

isoxsuprine

Development stage
Phase 2
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Isoxsuprine is a small molecule vasodilator and beta-adrenergic agonist used to treat conditions caused by poor blood circulation, such as peripheral vascular disease (including arteriosclerosis obliterans, Buerger's disease), Raynaud's disease, and cerebrovascular insufficiency. It acts primarily by relaxing vascular and uterine smooth muscle through stimulation of beta-adrenergic receptors, leading to dilation of arteries—especially those supplying skeletal muscle—thereby improving blood flow. Isoxsuprine has also been used off-label for the prevention of premature labor and for menstrual pain. The drug was previously marketed under brand names such as Vasodilan but has been withdrawn from the U.S. market due to lack of evidence for efficacy in its approved indications[1][2][3][4][7][9].

Brand names
VasodilanTri Soxsuprine
Other names
isoxsuprine hydrochloride
02

Targets

GRIN2B (N-methyl-D-aspartate Receptor Subunit Combination: NR1a/NR2B)ADRA1A (α1A)CTH (Cystathionine gamma-lyase)ADRB2 (β2)

Beyond the preview

Go deeper on isoxsuprine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isoxsuprine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call